Related Experiment Videos
A comprehensive analysis and visualization of immune-related adverse events in lung cancer immunotherapy a
Xiongjie Li1, Fengyue Zhang2, Xuan Xu3
1Cardiothoracic Thyroid & Breast Surgery Department, Hubei Jianghan Oilfield General Hospital, No. T32, An Kang Road, Guanghua Subdistrict, Qianjiang, 433100, Hubei, China. surobert518@163.com.
Background:
Immune-related adverse events (irAEs) significantly impact the therapeutic efficacy of immune checkpoint inhibitors (ICIs) in lung cancer. However, a comprehensive understanding of the global research landscape and its evolution regarding irAEs is still lacking.
Methods:
We conducted a bibliometric analysis of 6787 publications from the Web of Science Core Collection (2015-2024) via CiteSpace and the R-bibliometrix package. The analyses included cocitation, coauthorship, and keyword burst detection to map collaborative networks, knowledge structure, and research trends.
Results:
Research output demonstrated a remarkable compound annual growth rate of 30.4%. INSERM (France) and US institutions appeared as central hubs in collaborative networks, whereas China-despite its high publication volume-showed more limited international integration, suggesting a productivity‑influence mismatch. The knowledge base comprises three clusters: clinical evidence, translational research, and fundamental immunology. Research themes evolved from initial tumor-agnostic safety reports to a focus on organ-specific irAEs and precision toxicology.
Conclusion:
This study delineates the rapidly evolving landscape of irAE research in lung cancer immunotherapy, highlighting key collaborative patterns, knowledge structures, and thematic shifts. The findings provide a foundational perspective for guiding future research directions.
Related Concept Videos
01:27Tumor Immunotherapy
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...